 <h1>Estradiol / norethindrone Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of estradiol/norethindrone include:</b> asthenia, dysmenorrhea, menstrual disease, pharyngitis, vaginitis, back pain, and mastalgia. <b>Other side effects include:</b> nervousness.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to estradiol/norethindrone: oral tablet</i></p><p>Other dosage forms:</p><ul><li>transdermal patch extended release</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. An increased risk of DVT, pulmonary embolism, stroke, myocardial infarction, and invasive breast cancer have been reported. An increased risk of probable dementia in postmenopausal women 65 years of age or older has also been reported. There is an increased risk of endometrial cancer in women with a uterus who use unopposed estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, estradiol / norethindrone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking estradiol / norethindrone:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills or fever</li>
<li>cold or flu-like symptoms</li>
<li>difficulty breathing</li>
<li>headache</li>
<li>itching of the vagina or genital area</li>
<li>nonmenstrual vaginal bleeding</li>
<li>pain during sexual intercourse</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>change in vaginal discharge</li>
<li>chest pain, discomfort, or tightness in chest</li>
<li>clay-colored stools</li>
<li>clear or bloody discharge from the nipple</li>
<li>confusion</li>
<li>dark urine</li>
<li>difficulty speaking</li>
<li>difficulty swallowing</li>
<li>dizziness or lightheadedness</li>
<li>double vision</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>joint or muscle pain</li>
<li>loss of appetite</li>
<li>lump in the breast or under the arm</li>
<li>nausea and vomiting</li>
<li>noisy breathing</li>
<li>pain in the ankles or knees</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>pain or feeling of pressure in the pelvis</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>painful, red lumps under the skin, mostly on the legs</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>problems with memory or speech</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red, irritated eyes</li>
<li>redness or swelling of the breast</li>
<li>skin rash, hives, or itching</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>sudden shortness of breath or troubled breathing</li>
<li>sweating</li>
<li>trouble recognizing objects</li>
<li>trouble thinking and planning</li>
<li>trouble walking</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of estradiol / norethindrone may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>breast pain</li>
<li>cramps</li>
<li>crying</li>
<li>euphoria</li>
<li>mental depression</li>
<li>paranoia</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>trouble sleeping</li>
<li>weakness</li>
<li>weight gain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Changes in appetite</li>
<li>changes in sexual ability, desire, drive, or performance</li>
<li>excess air or gas in the stomach or intestines</li>
<li>increased hair growth, especially on the face</li>
<li>patchy brown or dark brown discoloration of the skin</li>
<li>trouble wearing contact lenses</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to estradiol / norethindrone: oral tablet, transdermal film extended release</i></p><h3>General</h3><p>The most common adverse events were vaginal bleeding and breast pain/tenderness.  Vaginal bleeding usually occurred in the first months of treatment.  Breast pain usually disappeared after a few months of therapy.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Vaginal hemorrhage (26%), breast pain (24%), post-menopausal bleeding (11%), endometrial thickening (10%), breast tenderness, menstruation irregular</p>
<p><b>Common</b> (1% to 10%): Ovarian cyst, uterine fibroid, breast edema, breast enlargement, uterine fibroids aggravated, uterine fibroids recurrence, uterine fibroids</p>
<p><b>Uncommon</b> (0.1% to 1%): Endometrial hyperplasia, dysmenorrhea</p>
<p><b>Rare</b> (less than 0.1%): Fallopian tube cysts, endocervical polyps</p>
<p><b>Postmarketing reports</b>: Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow, breakthrough bleeding, spotting, increase in size of uterine leiomyomata, change in amount of cervical secretion, changes in cervical ectropion, pre-menstrual-like syndrome, cystitis-like syndrome, nipple discharge, galactorrhea, fibrocystic breast changes, vulvovaginal pruritus<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (22%)</p>
<p><b>Common</b> (1% to 10%): Migraine or migraine aggravated, dizziness</p>
<p><b>Rare</b> (less than 0.1%): Paresthesia</p>
<p><b>Postmarketing reports</b>: Dizziness, exacerbation of epilepsy, dementia, chorea, stroke<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Blood pressure increase</p>
<p><b>Uncommon</b> (0.1% to 1%): Thrombophlebitis superficial, venous thromboembolism</p>
<p><b>Rare</b> (less than 0.1%): Thrombophlebitis deep, deep venous thromboembolism</p>
<p><b>Postmarketing reports</b>: Deep and superficial vein thrombosis, thrombophlebitis, myocardial infarction, stroke, hypertension aggravated<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (11%)</p>
<p><b>Common</b> (1% to 10%): Gastroenteritis, diarrhea, abdominal pain, abdominal distention, abdominal discomfort</p>
<p><b>Uncommon</b> (0.1% to 1%): Flatulence, bloating</p>
<p><b>Postmarketing reports</b>: Vomiting, abdominal cramps, pancreatitis, dyspepsia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, emotional lability, depression or depression aggravated</p>
<p><b>Uncommon</b> (0.1% to 1%): Nervousness, changes in libido</p>
<p><b>Postmarketing reports</b>: Mental depression, mood disturbances, irritability, anxiety<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Accidental injury (17%)</p>
<p><b>Common</b> (1% to 10%): Weight increase, weight decreased, edema peripheral, pain, asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Drug ineffective</p>
<p><b>Postmarketing reports</b>: Fatigue, edema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (10%)</p>
<p><b>Common</b> (1% to 10%): Pain in extremity, leg cramps<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (21%), upper respiratory tract infection (18%), sinusitis (15%)</p>
<p><b>Common</b> (1% to 10%): Infection viral, moniliasis genital, genital candidiasis or vaginitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne, rash, pruritus, dry skin</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, hirsutism, urticaria, skin reactions, skin discoloration</p>
<p><b>Postmarketing reports</b>: Chloasma or melasma that may persist when drug is discontinued, erythema multiforme, erythema nodosum, hemorrhagic eruption, loss of scalp hair, seborrhea, skin rash, seborrhea, angioneurotic edema<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Breast cancer</p>
<p><b>Rare</b> (less than 0.1%): Uterine leiomyoma</p>
<p><b>Postmarketing reports</b>: Ovarian cancer, endometrial cancer<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Rare</b> (less than 0.1%): Allergic reaction</p>
<p><b>Postmarketing reports</b>: Anaphylactoid/anaphylactic reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Rare</b> (less than 0.1%): Pulmonary embolism, asthma</p>
<p><b>Postmarketing reports</b>: Exacerbation of asthma<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Gallbladder disease, gallstones, transaminases increased</p>
<p><b>Rare</b> (less than 0.1%): Cholelithiasis</p>
<p><b>Postmarketing reports</b>: Cholestatic jaundice, gallbladder disease, cholelithiasis aggravated, cholelithiasis recurrence<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Fluid retention</p>
<p><b>Postmarketing reports</b>: Changes in appetite, increased triglycerides<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Retinal vascular thrombosis, intolerance to contact lenses, visual disturbances<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Amabelz (estradiol-norethindrone)." Lupin Pharmaceuticals Inc, Baltimore, MD. </p><p id="ref_4">4. "Product Information. Activella (estradiol-norethindrone)." Gemini Laboratories, Bridgewater, NJ. </p><p id="ref_5">5. "Product Information. Mimvey (estradiol-norethindrone)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_6">6. "Product Information. Lopreeza (estradiol-norethindrone)." Amneal Pharmaceuticals, Glasgow, KY. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about estradiol / norethindrone</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>57 Reviews</li>
<li>Drug class: sex hormone combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Estradiol and norethindrone transdermal</li>
<li>Estradiol and norethindrone &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Estradiol and norethindrone Transdermal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>CombiPatch, Activella, Mimvey, Lopreeza</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Atrophic Vaginitis</li>
<li>Atrophic Urethritis</li>
<li>Hypoestrogenism</li>
<li>Postmenopausal Symptoms</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to estradiol / norethindrone: oral tablet, transdermal film extended release</i></p><h3>General</h3><p>The most common adverse events were vaginal bleeding and breast pain/tenderness.  Vaginal bleeding usually occurred in the first months of treatment.  Breast pain usually disappeared after a few months of therapy.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Vaginal hemorrhage (26%), breast pain (24%), post-menopausal bleeding (11%), endometrial thickening (10%), breast tenderness, menstruation irregular</p><p><b>Common</b> (1% to 10%): Ovarian cyst, uterine fibroid, breast edema, breast enlargement, uterine fibroids aggravated, uterine fibroids recurrence, uterine fibroids</p><p><b>Uncommon</b> (0.1% to 1%): Endometrial hyperplasia, dysmenorrhea</p><p><b>Rare</b> (less than 0.1%): Fallopian tube cysts, endocervical polyps</p><p><b>Postmarketing reports</b>: Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow, breakthrough bleeding, spotting, increase in size of uterine leiomyomata, change in amount of cervical secretion, changes in cervical ectropion, pre-menstrual-like syndrome, cystitis-like syndrome, nipple discharge, galactorrhea, fibrocystic breast changes, vulvovaginal pruritus<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (22%)</p><p><b>Common</b> (1% to 10%): Migraine or migraine aggravated, dizziness</p><p><b>Rare</b> (less than 0.1%): Paresthesia</p><p><b>Postmarketing reports</b>: Dizziness, exacerbation of epilepsy, dementia, chorea, stroke<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Blood pressure increase</p><p><b>Uncommon</b> (0.1% to 1%): Thrombophlebitis superficial, venous thromboembolism</p><p><b>Rare</b> (less than 0.1%): Thrombophlebitis deep, deep venous thromboembolism</p><p><b>Postmarketing reports</b>: Deep and superficial vein thrombosis, thrombophlebitis, myocardial infarction, stroke, hypertension aggravated<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (11%)</p><p><b>Common</b> (1% to 10%): Gastroenteritis, diarrhea, abdominal pain, abdominal distention, abdominal discomfort</p><p><b>Uncommon</b> (0.1% to 1%): Flatulence, bloating</p><p><b>Postmarketing reports</b>: Vomiting, abdominal cramps, pancreatitis, dyspepsia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, emotional lability, depression or depression aggravated</p><p><b>Uncommon</b> (0.1% to 1%): Nervousness, changes in libido</p><p><b>Postmarketing reports</b>: Mental depression, mood disturbances, irritability, anxiety<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Accidental injury (17%)</p><p><b>Common</b> (1% to 10%): Weight increase, weight decreased, edema peripheral, pain, asthenia</p><p><b>Uncommon</b> (0.1% to 1%): Drug ineffective</p><p><b>Postmarketing reports</b>: Fatigue, edema<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (10%)</p><p><b>Common</b> (1% to 10%): Pain in extremity, leg cramps<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (21%), upper respiratory tract infection (18%), sinusitis (15%)</p><p><b>Common</b> (1% to 10%): Infection viral, moniliasis genital, genital candidiasis or vaginitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne, rash, pruritus, dry skin</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, hirsutism, urticaria, skin reactions, skin discoloration</p><p><b>Postmarketing reports</b>: Chloasma or melasma that may persist when drug is discontinued, erythema multiforme, erythema nodosum, hemorrhagic eruption, loss of scalp hair, seborrhea, skin rash, seborrhea, angioneurotic edema<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Breast cancer</p><p><b>Rare</b> (less than 0.1%): Uterine leiomyoma</p><p><b>Postmarketing reports</b>: Ovarian cancer, endometrial cancer<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Rare</b> (less than 0.1%): Allergic reaction</p><p><b>Postmarketing reports</b>: Anaphylactoid/anaphylactic reactions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Rare</b> (less than 0.1%): Pulmonary embolism, asthma</p><p><b>Postmarketing reports</b>: Exacerbation of asthma<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Gallbladder disease, gallstones, transaminases increased</p><p><b>Rare</b> (less than 0.1%): Cholelithiasis</p><p><b>Postmarketing reports</b>: Cholestatic jaundice, gallbladder disease, cholelithiasis aggravated, cholelithiasis recurrence<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Fluid retention</p><p><b>Postmarketing reports</b>: Changes in appetite, increased triglycerides<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Retinal vascular thrombosis, intolerance to contact lenses, visual disturbances<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Amabelz (estradiol-norethindrone)." Lupin Pharmaceuticals Inc, Baltimore, MD. </p><p id="ref_4">4. "Product Information. Activella (estradiol-norethindrone)." Gemini Laboratories, Bridgewater, NJ. </p><p id="ref_5">5. "Product Information. Mimvey (estradiol-norethindrone)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_6">6. "Product Information. Lopreeza (estradiol-norethindrone)." Amneal Pharmaceuticals, Glasgow, KY. </p><h2>More about estradiol / norethindrone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>57 Reviews</li>
<li>Drug class: sex hormone combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Estradiol and norethindrone transdermal</li>
<li>Estradiol and norethindrone &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Estradiol and norethindrone Transdermal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Atrophic Vaginitis</li>
<li>Atrophic Urethritis</li>
<li>Hypoestrogenism</li>
<li>Postmenopausal Symptoms</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>